title: Clinical and molecular features of one case of human infection with Anaplasma phagocytophilum from Podlaskie Province in eastern Poland.
abstract: The article focuses on the clinical and laboratory diagnosis of human granulocytic anaplasmosis (HGA) caused by Anaplasma phagocytophilum infection in one of 28 patients (3.6%; n=1/28 tested samples) with early Lyme borreliosis. The clinical and laboratory results of a 42-year-old patient fulfilled criteria of confirm anaplasmosis and suggest an acute stage of illness. The described case provides strong presumptive evidence that infection in this patient was acquired with a pathogenic strain of A. phagocytophilum through a tick bite. A positive DNA with PCR for A. phagocytophilum infection was sequenced and analyzed phylogenetically. Physicians should consider the possibility of anaplasmosis in patients with early Lyme borreliosis, and A. phagocytophilum should be considered as a differential diagnosis in all patients from an endemic region of potential high risk factors for tick-borne diseases.
authors.affiliation: Department of Parasitology, University of Warsaw, Poland.
authors.forename: Renata
authors.initials: R
authors.lastname: Welc-Falęciak
authors.affiliation: Department of Parasitology, University of Warsaw, Poland.
authors.forename: Maciej
authors.initials: M
authors.lastname: Kowalec
authors.affiliation: Department of Infectious Diseases and Neuroinfections, Medical University, Białystok, Poland.
authors.forename: Joanna
authors.initials: J
authors.lastname: Zajkowska
authors.affiliation: Department of Infectious Diseases and Neuroinfections, Medical University, Białystok, Poland.
authors.forename: Sławomir A
authors.initials: SA
authors.lastname: Pancewicz
authors.affiliation: Department of Parasitology, University of Warsaw, Poland.
authors.forename: Edward
authors.initials: E
authors.lastname: Siński
mesh_terms: D000328:Adult; D000658:Amoxicillin / Q000627:therapeutic use; D041081:Anaplasma phagocytophilum / Q000235:genetics / Q000302:isolation & purification* / Q000378:metabolism; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001426:Bacterial Proteins / Q000235:genetics / Q000378:metabolism; D002443:Ceftriaxone / Q000627:therapeutic use; D018833:Chaperonins / Q000235:genetics / Q000378:metabolism; D060085:Coinfection / Q000382:microbiology; D003937:Diagnosis, Differential; D016873:Ehrlichiosis / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D008193:Lyme Disease / Q000382:microbiology; D008297:Male; D008969:Molecular Sequence Data; D010802:Phylogeny; D011044:Poland; D012336:RNA, Ribosomal, 16S / Q000235:genetics / Q000378:metabolism; D017422:Sequence Analysis, DNA; D017282:Tick-Borne Diseases / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; C097970:GroESL protein, Bacteria; D012336:RNA, Ribosomal, 16S; D002443:Ceftriaxone; D000658:Amoxicillin; D018833:Chaperonins